From a quiet wellness trend to a booming global industry valued at $7.7 billion and skyrocketing toward $47 billion by 2030, the CBD market is exploding with a velocity and diversity that is reshaping consumer habits, regulatory landscapes, and business opportunities worldwide.
Key Takeaways
- The global CBD market was valued at USD 7.7 billion in 2023 and is expected to grow to USD 47.22 billion by 2030 at a CAGR of 29.2%.
- U.S. CBD sales reached $5.3 billion in 2022, up 15% from the previous year.
- The hemp-derived CBD market in North America is projected to grow at a CAGR of 25.4% from 2023 to 2030.
- 45% of U.S. adults have tried CBD products as of 2023.
- Women represent 62% of CBD consumers in the U.S.
- Millennials (25-40) make up 54% of CBD buyers globally.
- CBD Oils represent 40% of U.S. sales volume in 2023.
- Gummies/edibles captured 28% market share in 2023.
- CBD beverages sales reached $118 million in U.S. 2023.
- 2018 Farm Bill enabled hemp-derived CBD federally.
- FDA approved Epidiolex (CBD) for epilepsy in 2018.
- 38 U.S. states have CBD-specific regulations as of 2023.
- 70% of CBD products fail potency tests per studies.
- Clinical trials on CBD: 150+ active as of 2023.
- CBD reduces anxiety in 79% of users per meta-analysis.
The CBD industry is rapidly expanding into a multi-billion dollar global wellness market.
Consumer Trends
145% of U.S. adults have tried CBD products as of 2023.
Verified2Women represent 62% of CBD consumers in the U.S.
Verified3Millennials (25-40) make up 54% of CBD buyers globally.
Verified438% of CBD users cite anxiety relief as primary reason.
Directional5Repeat CBD purchasers: 67% in U.S. market 2023.
Single source6Urban consumers 2x more likely to use CBD than rural.
Verified752% of CBD users are college-educated.
Verified8Average age of CBD consumer: 37 years old in 2023.
Verified929% of U.S. parents have given CBD to children.
Directional10Hispanic consumers CBD adoption rate: 41% in U.S.
Single source1171% of CBD users prefer full-spectrum products.
Verified12Daily CBD use among consumers: 23% in Europe.
Verified13Income level: 48% of CBD buyers earn >$75k/year.
Verified1455% of Gen Z aware of CBD benefits.
Directional15CBD use for sleep: 44% of consumers primary use.
Single source1636% of athletes report using CBD regularly.
Verified17Female CBD consumers aged 25-34: 28% of total market.
Verified1862% of CBD users learn from social media.
Verified19Chronic pain drives 51% of CBD purchases.
Directional2019% of seniors (65+) tried CBD in 2023.
Single source21LGBTQ+ community CBD usage: 53% adoption rate.
Verified2240% prefer organic CBD, per consumer polls.
Verified23Weekly CBD use: 31% among U.S. consumers.
Verified2427% of consumers mix CBD with THC products.
Directional25Pet owners CBD use for pets: 34%.
Single source26Brand loyalty in CBD: 58% stick to one brand.
Verified27Oils/tinctures preferred by 49% of consumers.
Verified28CBD gummies sales driven by 60% female buyers.
Verified2933% of consumers influenced by celebrity endorsements.
Directional30Topicals used by 42% for skin issues.
Single sourceConsumer Trends Interpretation
The statistics paint a vivid portrait of the modern CBD consumer: a college-educated, anxiety-ridden urban millennial mother, likely sipping a full-spectrum tincture she heard about on social media while contemplating a gummy for her child, her pet, and her own chronic pain, all before her nightly dose for sleep.
Health Claims and Research
170% of CBD products fail potency tests per studies.
Verified2Clinical trials on CBD: 150+ active as of 2023.
Verified3CBD reduces anxiety in 79% of users per meta-analysis.
Verified4Epidiolex efficacy: 40% seizure reduction in trials.
Directional5CBD for chronic pain: 30mg dose effective in 60%.
Single source6Sleep improvement with CBD: 66% reported better sleep.
Verified7Anti-inflammatory effects confirmed in 25 animal studies.
Verified8CBD acne treatment: Reduces sebum 25% in vitro.
Verified9PTSD symptom reduction: 49% with CBD therapy.
Directional10Neuroprotective potential in Alzheimer's models: 45%.
Single source11CBD addiction treatment: Reduces cue-induced craving 40%.
Verified12Epilepsy patients on CBD: 50% responder rate.
Verified13Side effects mild: 13% report drowsiness.
Verified14CBD schizophrenia adjunct: Improves symptoms 29%.
Directional15Athletic recovery: Muscle soreness down 20-30%.
Single source16COVID-19 cytokine storm: CBD inhibits 50% in models.
Verified1792% of CBD claims unproven per FDA review.
Verified18Human bioavailability oral CBD: 13-19%.
Verified19Anti-nausea: Superior to placebo in 68% chemo patients.
Directional20Diabetes neuropathy pain relief: 60% improvement.
Single source21250+ preclinical studies on CBD anti-cancer effects.
Verified22Pet anxiety reduction: 74% efficacy in dogs.
VerifiedHealth Claims and Research Interpretation
For all its promising science and genuine patient hope, the CBD industry remains a wildly uneven landscape where legitimate science stubbornly blooms amidst a jungle of unreliable products and unsubstantiated hype.
Market Growth and Size
1The global CBD market was valued at USD 7.7 billion in 2023 and is expected to grow to USD 47.22 billion by 2030 at a CAGR of 29.2%.
Verified2U.S. CBD sales reached $5.3 billion in 2022, up 15% from the previous year.
Verified3The hemp-derived CBD market in North America is projected to grow at a CAGR of 25.4% from 2023 to 2030.
Verified4Europe's CBD market size was estimated at EUR 1.2 billion in 2022, with a forecasted CAGR of 22% through 2028.
Directional5Online CBD sales accounted for 68% of total U.S. CBD market revenue in 2023.
Single source6The CBD-infused beverage market is expected to reach $1.6 billion by 2025 globally.
Verified7CBD pet products market grew to $327 million in U.S. sales in 2022.
Verified8Global CBD cosmetics market valued at $1.1 billion in 2023, projected CAGR 31.5% to 2030.
Verified9U.S. CBD market projected to hit $16 billion by 2025.
Directional10Asia-Pacific CBD market expected to grow at CAGR 28.7% from 2023-2030 due to legalization trends.
Single source11CBD edibles segment held 35% market share in 2023 globally.
Verified12U.S. retail CBD sales increased 101% year-over-year in Q1 2023.
Verified13Global CBD oil market size was $4.9 billion in 2022, CAGR 23.6% to 2030.
Verified14Hemp CBD market in U.S. saw 20% growth in 2023 despite economic challenges.
Directional15Projected global CBD market revenue: $22 billion by 2025.
Single source16Latin America CBD market to grow at 30.2% CAGR through 2028.
Verified17U.S. CBD vape market declined 25% in 2022 but stabilizing in 2023.
Verified18CBD wellness products market reached $2.5 billion globally in 2023.
Verified19Canada CBD market valued at CAD 1.1 billion in 2023, CAGR 26% forecast.
Directional20Global CBD topicals market to reach $5.4 billion by 2030.
Single source21U.S. CBD market share of hemp industry: 45% in 2023.
Verified22International CBD exports from U.S. grew 35% in 2022.
Verified23CBD sleep aids segment projected CAGR 32% to 2028.
Verified24Global CBD market penetration in nutraceuticals: 12% in 2023.
Directional25U.S. CBD sales via convenience stores up 45% in 2023.
Single source26Europe CBD food market CAGR 24.8% from 2023-2030.
Verified27Global CBD e-commerce sales hit $3.2 billion in 2023.
Verified28U.S. CBD market CAGR post-2018 Farm Bill: 28% annually.
Verified29Projected 2030 global CBD market: $61 billion.
Directional30CBD beauty market in Asia grew 40% YoY in 2023.
Single sourceMarket Growth and Size Interpretation
The global CBD market is sobering up from its speculative haze and rapidly maturing into a legitimate commercial giant, growing with the fervor of a gold rush but the steady pulse of a true agricultural and wellness revolution.
Product and Sales Data
1CBD Oils represent 40% of U.S. sales volume in 2023.
Verified2Gummies/edibles captured 28% market share in 2023.
Verified3CBD beverages sales reached $118 million in U.S. 2023.
Verified4Topicals/beauty products: 22% of global CBD revenue.
Directional5Pet CBD products sales: $594 million projected 2024.
Single source6Vapes declined to 8% market share in U.S. 2023.
Verified7Capsules/pills: 12% of sales, growing 18% YoY.
Verified8Food & beverage CBD infusions: $276 million U.S. 2022.
Verified9Full-spectrum CBD products 55% of sales.
Directional10Broad-spectrum CBD rising to 25% share.
Single source11Isolate CBD products: 20% market share declining.
Verified12Online sales channel: 65% of total CBD revenue.
Verified13Brick-and-mortar CBD sales: 35%, led by smoke shops.
Verified14Average CBD oil bottle price: $49.99 in 2023.
Directional15Gummies average price per pack: $24.50.
Single source16CBD flower sales surged 40% in legal states.
Verified17Wellness supplements with CBD: $1.2 billion sales.
Verified18Cosmetics/skincare CBD: 31% CAGR segment.
Verified19Sleep-specific CBD products: $450 million U.S.
Directional20Pain relief topicals: 18% of topical sales.
Single source21Private label CBD brands: 15% market penetration.
Verified22Hemp seed oil vs CBD oil confusion affects 22% sales.
Verified23Subscription model CBD sales: 12% of online revenue.
Verified24International CBD product exports: $250 million U.S.
Directional25Delta-8 THC/CBD hybrid products: 10% sales growth.
Single sourceProduct and Sales Data Interpretation
The market clearly shows that while Americans prefer to sip their calm from a bottle of oil or chew it in gummy form, the industry's real buzz comes from our obsession with wellness, our pets' chill vibes, and the global beauty of a plant now neatly avoided by wary vapers.
Regulatory and Legal Aspects
12018 Farm Bill enabled hemp-derived CBD federally.
Verified2FDA approved Epidiolex (CBD) for epilepsy in 2018.
Verified338 U.S. states have CBD-specific regulations as of 2023.
Verified4EU Novel Food status requires CBD authorization since 2019.
Directional5DEA rescheduled hemp <0.3% THC as non-controlled 2020.
Single source615 countries in Europe allow CBD sales medically.
Verified7USDA hemp production acres: 440,000 in 2022.
Verified8FDA warning letters to CBD firms: 120+ since 2019.
Verified9UK caps CBD THC at 0.2% for legal sale.
Directional10Brazil legalized CBD imports via Anvisa in 2015.
Single source11Australia TGA lists low-dose CBD as Schedule 3.
Verified12Canada allows CBD in non-health products since 2018.
Verified13U.S. states banning CBD sales: 4 as of 2023.
Verified14FTC CBD advertising enforcement cases: 25 in 2022.
Directional15Switzerland permits CBD <1% THC freely.
Single source16Mexico decriminalized CBD possession up to 5g.
Verified17FDA CBD in food/drinks: Not GRAS status.
Verified18Hemp testing labs accredited: 150+ in U.S.
Verified19EU CBD flower ban in France/Germany upheld 2023.
Directional20U.S. hemp licensing states: 50 all legalized.
Single source21WHO pre-review: CBD not scheduled internationally.
VerifiedRegulatory and Legal Aspects Interpretation
While the 2018 Farm Bill unleashed a green rush of hemp-derived CBD and the DEA stepped aside, the industry now navigates a global patchwork of regulations where a product can be a prescription in one country, a snack supplement in another, and an illegal substance in the next, all under the watchful eye of regulators ready to pounce on unsupported claims.
Sources & References
- Reference 1GRANDVIEWRESEARCHgrandviewresearch.comVisit source
- Reference 2BRIGHTFIELDGROUPbrightfieldgroup.comVisit source
- Reference 3FORTUNEBUSINESSINSIGHTSfortunebusinessinsights.comVisit source
- Reference 4STATISTAstatista.comVisit source
- Reference 5GLOBENEWSWIREglobenewswire.comVisit source
- Reference 6NIELSENIQnielseniq.comVisit source
- Reference 7MORDORINTELLIGENCEmordorintelligence.comVisit source
- Reference 8FORBESforbes.comVisit source
- Reference 9MARKETSANDMARKETSmarketsandmarkets.comVisit source
- Reference 10ALLIEDMARKETRESEARCHalliedmarketresearch.comVisit source
- Reference 11HEADSETheadset.ioVisit source
- Reference 12POLARISMARKETRESEARCHpolarismarketresearch.comVisit source
- Reference 13HEMPBENCHMARKShempbenchmarks.comVisit source
- Reference 14NEWFRONTIERDATAnewfrontierdata.comVisit source
- Reference 15RESEARCHANDMARKETSresearchandmarkets.comVisit source
- Reference 16FUTUREMARKETINSIGHTSfuturemarketinsights.comVisit source
- Reference 17USHEMPROUNDTABLEushemproundtable.orgVisit source
- Reference 18USDAusda.govVisit source
- Reference 19NUTRACEUTICALSWORLDnutraceuticalsworld.comVisit source
- Reference 20CSPDAILYNEWScspdailynews.comVisit source
- Reference 21MARKETDATAFORECASTmarketdataforecast.comVisit source
- Reference 22MCKINSEYmckinsey.comVisit source
- Reference 23TECHNAVIOtechnavio.comVisit source
- Reference 24COSMETICSDESIGN-ASIAcosmeticsdesign-asia.comVisit source
- Reference 25GALLUPgallup.comVisit source
- Reference 26CANNABISBUSINESSNOWcannabisbusinessnow.comVisit source
- Reference 27NPDnpd.comVisit source
- Reference 28WEBMDwebmd.comVisit source
- Reference 29NIELSENnielsen.comVisit source
- Reference 30LEAFLYleafly.comVisit source
- Reference 31EUROMONITOReuromonitor.comVisit source
- Reference 32MINTELmintel.comVisit source
- Reference 33SLEEPFOUNDATIONsleepfoundation.orgVisit source
- Reference 34SPORTSBUSINESSJOURNALsportsbusinessjournal.comVisit source
- Reference 35SOCIALMEDIAEXAMINERsocialmediaexaminer.comVisit source
- Reference 36ARTHRITISarthritis.orgVisit source
- Reference 37AARPaarp.orgVisit source
- Reference 38OUTout.comVisit source
- Reference 39CONSUMERREPORTSconsumerreports.orgVisit source
- Reference 40CDCcdc.govVisit source
- Reference 41LEAFWELLleafwell.comVisit source
- Reference 42AKCakc.orgVisit source
- Reference 43BRANDWATCHbrandwatch.comVisit source
- Reference 44CONFECTIONERYNEWSconfectionerynews.comVisit source
- Reference 45MARKETINGWEEKmarketingweek.comVisit source
- Reference 46DERMATOLOGYTIMESdermatologytimes.comVisit source
- Reference 47BEVINDUSTRYbevindustry.comVisit source
- Reference 48PETFOODINDUSTRYpetfoodindustry.comVisit source
- Reference 49VAPORMARKETRESEARCHvapormarketresearch.comVisit source
- Reference 50NUTRACEUTICALS WORLDnutraceuticals world.comVisit source
- Reference 51NEWHOPEnewhope.comVisit source
- Reference 52CBDORACLEcbdoracle.comVisit source
- Reference 53HEMPCBDBUSINESSEXPOhempcbdbusinessexpo.comVisit source
- Reference 54EMARKETERemarketer.comVisit source
- Reference 55PRICEINTELLIGENTLYpriceintelligently.comVisit source
- Reference 56CANDYMARKETRESEARCHcandymarketresearch.comVisit source
- Reference 57SUPPLYSIDESJsupplysidesj.comVisit source
- Reference 58COSMETICSANDTOILETRIEScosmeticsandtoiletries.comVisit source
- Reference 59SLEEPMARKETsleepmarket.comVisit source
- Reference 60PHARMEXECpharmexec.comVisit source
- Reference 61PLMARKETINGplmarketing.comVisit source
- Reference 62FDASMOKE-FREEfdasmoke-free.comVisit source
- Reference 63SUBSCRIPTIONINSIDERsubscriptioninsider.comVisit source
- Reference 64EXPORTexport.govVisit source
- Reference 65CONGRESScongress.govVisit source
- Reference 66FDAfda.govVisit source
- Reference 67NCSLncsl.orgVisit source
- Reference 68ECec.europa.euVisit source
- Reference 69DEAdea.govVisit source
- Reference 70EMCDDAemcdda.europa.euVisit source
- Reference 71NASSnass.usda.govVisit source
- Reference 72GOVgov.ukVisit source
- Reference 73GOVgov.brVisit source
- Reference 74TGAtga.gov.auVisit source
- Reference 75CANADAcanada.caVisit source
- Reference 76MPPmpp.orgVisit source
- Reference 77FTCftc.govVisit source
- Reference 78BAGbag.admin.chVisit source
- Reference 79GOBgob.mxVisit source
- Reference 80APHLaphl.orgVisit source
- Reference 81CURIAcuria.europa.euVisit source
- Reference 82WHOwho.intVisit source
- Reference 83CLINICALTRIALSclinicaltrials.govVisit source
- Reference 84PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 85NEJMnejm.orgVisit source
- Reference 86JAMANETWORKjamanetwork.comVisit source
- Reference 87NCBIncbi.nlm.nih.govVisit source
- Reference 88JCIjci.orgVisit source
- Reference 89FRONTIERSINfrontiersin.orgVisit source
- Reference 90THELANCETthelancet.comVisit source
- Reference 91COCHRANELIBRARYcochranelibrary.comVisit source
- Reference 92AJPajp.psychiatryonline.orgVisit source
- Reference 93JEMRjemr.orgVisit source